155 related articles for article (PubMed ID: 21774109)
1. UK’s adopts systematic approach to personalised cancer medicine.
Fricker J
Mol Oncol; 2011 Jun; 5(3):217-9. PubMed ID: 21774109
[No Abstract] [Full Text] [Related]
2. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
3. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; van Saase L; van der Graaff M; Gijzen J; Sleijfer S; Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; van der Velden DL; van Werkhoven E; Retel VP; van Harten WH; Huitema ADR; Timmers L; Gelderblom H; Verheul HMW; Voest EE
Ann Oncol; 2019 May; 30(5):663-665. PubMed ID: 31038154
[No Abstract] [Full Text] [Related]
4. The value proposition of molecular medicine.
Waldman SA; Terzic A
Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
[No Abstract] [Full Text] [Related]
5. Perspective: The precision-oncology illusion.
Prasad V
Nature; 2016 Sep; 537(7619):S63. PubMed ID: 27602743
[No Abstract] [Full Text] [Related]
6. Precision Medicine.
Weil AR
Health Aff (Millwood); 2018 May; 37(5):687. PubMed ID: 29733714
[No Abstract] [Full Text] [Related]
7. Precision medicine and the rapidly approaching future of cancer management.
Markman M
Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP207-8, cover. PubMed ID: 23301708
[No Abstract] [Full Text] [Related]
8. Cancer-gene testing ramps up.
Callaway E
Nature; 2010 Oct; 467(7317):766-7. PubMed ID: 20944708
[No Abstract] [Full Text] [Related]
9. How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.
Seo MK; Cairns J
BMC Cancer; 2021 Sep; 21(1):980. PubMed ID: 34470603
[TBL] [Abstract][Full Text] [Related]
10. Perspective on Precision Medicine in Oncology.
Johnson TM
Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Nau JY
Rev Med Suisse; 2017 May; 13(564):1126-1127. PubMed ID: 28639780
[No Abstract] [Full Text] [Related]
12. Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble B
Scand J Clin Lab Invest Suppl; 2016; 245():S6-S11. PubMed ID: 27426412
[TBL] [Abstract][Full Text] [Related]
13. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
14. UK cancer genetics gets personal.
Wiseman D; Tuff A; Peach J
Nature; 2011 Jul; 475(7354):37. PubMed ID: 21734693
[No Abstract] [Full Text] [Related]
15. Tackling the UK's alcohol problems.
Siva N
Lancet; 2015 Jul; 386(9989):121-2. PubMed ID: 26194383
[No Abstract] [Full Text] [Related]
16. Precision Medicine.
Health Aff (Millwood); 2018 May; 37(5):688-689. PubMed ID: 29733721
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
18. Tumour-agnostic therapies.
Looney AM; Nawaz K; Webster RM
Nat Rev Drug Discov; 2020 Jun; 19(6):383-384. PubMed ID: 32494047
[No Abstract] [Full Text] [Related]
19. The science of precision prevention of cancer.
Vineis P; Wild CP
Lancet Oncol; 2017 Aug; 18(8):997-998. PubMed ID: 28759370
[No Abstract] [Full Text] [Related]
20. A decade of promises in personalised cancer medicine: is the honeymoon over?
Ward RL
Med J Aust; 2014 Feb; 200(3):132-3. PubMed ID: 24528411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
